Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
about
Immunologic aspect of ovarian cancer and p53 as tumor antigen.Interleukin 12: still a promising candidate for tumor immunotherapy?Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Cloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer.Targeting p53 as a general tumor antigen.Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.An overview of cancer immunotherapy.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathwayImmune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.Synthetic peptides as cancer vaccines.Helper T cells, dendritic cells and CTL Immunity.Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMaxIL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcomaTherapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activityTherapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.Tumor-infiltrating T lymphocytes: friends or foes?Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect.Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells.Molecular alterations in pediatric sarcomas: potential targets for immunotherapyRole of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activityAdenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan AIL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.Effect of interleukin 12 on tumor induction by 3-methylcholanthreneHarnessing human dendritic cell subsets for medicine.Dendritic cells and humoral immunity in humans.Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature.Melanoma vaccines: developments over the past 10 years.Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells.DNA vaccines for cancer therapy.Interleukin-12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis.Interleukin-12 induces an effective antitumor response in malignant mesothelioma.Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms.
P2860
Q24814703-E7BE5C08-C6BF-4C7C-AFF2-1BB051625B9DQ26861559-C865BB47-92B1-4BCD-BE0A-86DF7DFCFC1CQ30436422-C7BF48D4-20AF-4D7C-8A19-F2FF46442388Q30769959-525CE9E6-7704-499A-B97C-413B35742E82Q30832187-2EF5299E-E1D0-4F59-825A-0024827B0099Q33638172-938BF69E-D6CD-4B3B-B617-71148501EEF5Q33866879-9CCCB5FA-DD45-4EBE-AEB4-66766CE748D4Q33940388-B1D69723-7E98-46E8-B5ED-C843706D18CEQ33999909-9AB828F7-6244-4E4A-AC09-5E60C7CCC48AQ34314210-0CE3EFA6-0393-445E-AB43-71AA8509A01AQ34353878-491E9D68-6891-4FDD-8AC7-C99D0B32A593Q34972916-AE1D57E2-E892-4382-953E-8E247880819FQ35675903-794449D8-8542-4D58-8C16-78946C65E1D0Q35790603-0317C9F2-4149-46BF-8AA8-9CDBEA3D708FQ35950374-967F249D-828A-4ADD-8654-76815E31AEE0Q36088999-CE890EE8-4138-4931-8551-3E8165819B1CQ36119828-A714F326-0546-4795-9416-3798E6A4E7CDQ36184608-7994E083-5933-4AC0-9F81-4C952CEF5819Q36291674-FB24C90B-822F-4BE0-A186-8C297017470DQ36366108-75C62ACF-7541-43CA-8512-8C89D3F778CFQ36376876-B7A49664-C733-48C8-AD0A-15D26D8EBBEDQ36381918-90E37B83-5EAE-4ED2-BA16-12D75EBA9BD7Q36401702-631D356C-0DE3-44E2-A575-4DFF4AFB88F2Q36473826-DE6E0284-D447-496C-A170-4B8E9CAAA7B3Q36617339-8CDDB159-920F-4A53-833A-2AD51FE7A09EQ36673885-F3534624-E795-46FC-8B6E-795EEB86804BQ36731317-D0FB5423-FD6C-41A7-B2D1-11F321596133Q36821572-6CB6E13B-AF17-467E-BEC4-C5712BC4344CQ37003339-AF8E5D49-CA2C-4579-93F8-DDAFC5D76763Q37219974-446C5AC6-44F5-46B4-88A1-A041DE209908Q37269591-A56A572C-D22C-4B63-AAD2-185B7C9BFCCDQ37700841-4BB2AA49-4D6B-465B-9D24-75BBF58BF360Q37716595-C95BBF05-4F4F-42FA-BE72-92A0CA32D30EQ37851520-6C54F604-FDCE-4D7A-A701-ED364EFAF396Q37892595-1111B659-12D0-4B96-ABAD-0B074691A480Q39117561-A7330A9E-298F-4729-887A-C08CB0729690Q40732047-80189A19-0A2D-48B4-B682-1C871D124232Q40764004-A337ED2A-FF37-40D1-ABC8-EEC001637D34Q40996460-6BA591FA-36D3-405F-90E6-D816D248F37BQ41062756-525B58F7-F11B-4107-BD4D-06D036434C31
P2860
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@ast
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@en
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@nl
type
label
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@ast
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@en
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@nl
prefLabel
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@ast
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@en
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@nl
P2093
P2860
P356
P1476
Influence of interleukin 12 on ...... st established Meth A sarcoma.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.6.2219
P407
P577
1995-03-01T00:00:00Z